Neutralization of HIV-1 subtypes: Implications for vaccine formulations

Journal of Medical Virology

Volumn 56, Issue 3, 1998, Pages 264-268

  Smith, Tracey Lee ^a   Van Rensburg, Estrelita J ^a   Engelbrecht, Susan ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Antibodies; PCR; South Africa; V3 loop sequences

Indexed keywords

GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; POLYMERASE CHAIN REACTION; SOUTH AFRICA; VACCINE PRODUCTION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS TYPING;

AIDS VACCINES; AMINO ACID SEQUENCE; CELL LINE; CELLS, CULTURED; HIV ANTIBODIES; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; POLYMERASE CHAIN REACTION;

HTLV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0031713226     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9071(199811)56:3<264::AID-JMV15>3.0.CO;2-E     Document Type: Article

References (28)

1. Albert J, Fenyö EM (1990): Simple, sensitive, and specific detection of human immunodeficiency virus type 1 in clinical samples by polymerase chain reaction with nested primers. Journal of Clinical Microbiology 28:1560-1564.
2. Becker MLB, Spracklen FHN, Becker WB (1985): Isolation of a lymphadenopathy-associated virus from a patient with the aquired immune deficiency syndrome. South African Medical Journal 68:144-147.
3. Blouin JC, Guzman EA, Foley BT (1996): Global variation in the HIV-1 V3 region. In Myers G, Korber B, Foley B, Jeang K-T, Mellors JW, Wain-Hobson S (eds): "Human retroviruses and AIDS 1996." Los Alamos, NM: Los Alamos National Laboratory.
4. Cheng-Mayer C, Homsy J, Evans LA, Levy JA (1988): Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proceedings of the National Academy of Sciences U.S.A. 85:2815-2819.
5. Dalgleish AG, Chanh TC, Kennedy RC, Kanda P, Clapham PR, Weiss RA (1988): Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 165: 209-215.
6. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR (1996): Identification of a major co-receptor for primary isolates of HIV-1. Nature 381:661-666.
7. Dietrich U, Grez M, von Briesen H, Panhans B, Geissendorfer M, Kuhnel H, Maniar J, Mahambre G, Becker WB, Becker ML, Rubsamen-Waigman H (1993): HIV-1 strains from India are highly divergent from prototypic African and US/European strains, but are linked to a South African isolate. AIDS 7:23-27.
8. + cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
9. Engelbrecht S, Laten JD, Smith T-L, van Rensburg EJ (1995): Identification of env subtypes in fourteen HIV type 1 isolates from South Africa. AIDS Research and Human Retroviruses 11:1269-1271.
10. Graham BS, Wright PF (1995): Candidate AIDS vaccines. New England Journal of Medicine 333:1331-1339.
11. Ho DD, Kaplan JC, Rackauskas IE, Gurney ME (1988): Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science 239:1021-1023.
12. Johnson VA, Byington RE (1990): Quantitative assays for virus infectivity. In Aldovini A, Walker BD (eds): "Techniques in HIV Research." New York: Stockton Press, pp 71-77.
13. Luo C-C, Tian C, Hu DJ, Kai M, Dondero T, Zheng X (1995): HIV-1 subtype in China. Lancet 345:1051-1052.
14. Mascola JR, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, Burke DS (1994): Two anti-genically distinct subtypes of human immunodeficiency virus type 1: Viral phenotype predicts neutralization serotype. Journal of Infectious Diseases 169:48-54.
15. Mascola JR, Louder MK, Surman SR, Vancott TC, Yu XF, Bradac J, Porter KR, Nelson KE, Girard M, McNeil JG, McCutchan FE, Birx DC, Burke DS (1996): Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. AIDS Research and Human Retroviruses 14: 1319-1328.
16. Moog C, Fleury HJA, Pellegrin I, Kirn A, and Aubertin M (1997): Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type-1 infected individuals. Journal of Virology 71:3734-3741.
17. Moore J, Trkola A (1997): HIV type 1 coreceptors, neutralization serotypes, and vaccine development. AIDS Research Human Retroviruses 13:733-736.
18. Moore JP, Sattentau QJ, Yoshiyama H Thali M, Charles M, Sullivan N, Poon SW, Fung MS, Traincard F, Pinkus M (1993): Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains. Journal of Virology 67:6136-6151.
19. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD (1996): Inter-and intraclade neutralization of human immunodeficiency virus type 1: Genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes. Journal of Virology 70:427-444.
20. Myers G, Korber B, Foley B, Jeang K-T, Mellors JW, Wain-Hobson S (eds) (1996): "Humari Retroviruses and AIDS. Part III." Los Alamos, NM: Los Alamos National Laboratory.
21. Nyambi PN Nkengasong J, Peelers M, Simon F, Eberle J, Janssens W, Fransen K, Willems B, Vereecke K, Heyndrickx L, Piot P, van der Groen G (1995): Reduced capacity of antibodies from patients infected with human immunodeficiency virus type 1 (HIV-1) group O to neutralize primary isolates of HIV-1 group M viruses. Journal of Infectious Diseases 172:1228-1237.
22. Sanders-Buell E, Salminen M, McCutchan FE (1995): Sequencing primers for HIV-1. In Myers G, Korber B, Hahn BH, Jeang K-T, Mellors JW McCutchan E, Henderson LE, Pavlakis GN (eds): "Human Retroviruses and AIDS, Part III." Los Alamos, NM: Los Alamos National Laboratory.
23. UNAIDS/WHO working group on global HIV/AIDS and STD surveillance (1997): Report on the global HIV/AIDS epidemic.
24. Van Harmelen J, Wood R, Lambrick M, Rybicki EP, Williamson A-L, Williamson C (1997): An association between HIV-1 subtypes and mode of transmission in Cape Town, South Africa. AIDS 11:81-87.
25. Van Kuppeveld FJM, van der Logt JTM, Angulo AF, van Zoest MJ, Quint WG, Niesters HG, Galama JM, Melchers WJ (1992): Genus-and species-specific identification of mycoplasmas by 16S rRNA amplification. Applied Environmental Microbiology 58:2606-2615.
26. Vujcic LK, Quinnan GV Jr (1995): Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Research and Human Retroviruses 7:783-787.
27. Williamson C, Engelbrecht S, Lambrick M, van Rensburg EJ, Wood R, Bredell W, Williamson HL (1995): HIV-1 subtypes in different risk groups in South Africa. Lancet 346:782.
28. Wrin T, Loh TP, Vennari JC, Schuitemaker H, Nunberg JH (1995): Adaptation to persistent growth in H9 cell line renders a primary isolate of human immuno-deficiency virus type 1 sensitive to neutralization by vaccine sera. Journal of Virology 69:39-48.